Concepedia

Christopher M. Treleaven

CM

16

Publications

1.5K

Citations

16

H-Index

2005

Active since

Affiliations

SynZyme Technologies (United States)(Current)

Beth Israel Deaconess Medical Center

Harvard University

Nationwide Children's Hospital

The Ohio State University

Christopher M. Treleaven is an author at SynZyme Technologies (United States) specializing in medicine, neurology, and neuroscience.

Top concepts

Publications per year

2005–2022

16

Publications

16

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies

S. Pablo Sardi, Jennifer Clarke, Catherine Viel et al. · Proceedings of the National Academy of Sciences · 2013 · 242 citations · Full text

Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models

S. Pablo Sardi, Catherine Viel, Jennifer Clarke et al. · Proceedings of the National Academy of Sciences · 2017 · 196 citations · Full text

Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease

Lisa M. Stanek, S. Pablo Sardi, Bryan Mastis et al. · Human Gene Therapy · 2014 · 160 citations · Full text

, , +16

Delivery of AAV-IGF-1 to the CNS Extends Survival in ALS Mice Through Modification of Aberrant Glial Cell Activity

James C. Dodge, Amanda M. Haidet, Wendy Yang et al. · Molecular Therapy · 2008 · 157 citations · Full text

Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis

James C. Dodge, Christopher M. Treleaven, Joshua Pacheco et al. · Proceedings of the National Academy of Sciences · 2015 · 130 citations · Full text

Rows per page

1–5 of 16